OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300041$12.6758

Hubei Huitian New Materials Co Ltd

Specialty ChemicalsVerified

The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.7, suggesting it can cover short-term obligations but with limited buffer. The price-to-book ratio of 2.31 and price-to-tangible-book ratio of 2.31 indicate that the company's market value is trading at a premium to its book value. The enterprise value to EBITDA ratio of 33.61 suggests a high valuation relative to earnings, which may reflect investor expectations of future growth or industry-specific dynamics. Profitability metrics show a return on equity of 7.18% and a return on assets of 3.29%, both of which are below the typical thresholds for high-performing specialty chemical firms. The gross profit margin of 23.25% (calculated from gross profit of 1.03 billion CNY on revenue of 4.44 billion CNY) is in line with industry norms, but the operating margin of 6.21% (calculated from operating income of 275.31 million CNY) is relatively low, indicating potential cost pressures or pricing challenges. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment and geographic diversification increases exposure to sector-specific and regional economic risks. Looking ahead, the company is expected to see a 22.5% increase in revenue in the current fiscal year, based on analyst estimates of 0.49 CNY EPS compared to the actual 0.40 CNY EPS. However, the capital expenditure of -185.10 million CNY suggests a reduction in investment, which may impact long-term growth potential. The risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund operations or pursue strategic initiatives without external financing. Recent events include a strong buy recommendation from one analyst, with no other analyst ratings provided. The absence of additional analyst coverage may limit the availability of independent insights into the company's performance and prospects.

30-day price · 300041(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyHubei Huitian New Materials Co Ltd
Ticker300041.SZ
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Hubei Huitian New Materials Co Ltd is a Chinese specialty chemicals company that produces and sells chemical products, primarily serving industrial and manufacturing sectors.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.7, suggesting it can cover short-term obligations but with limited buffer. The price-to-book ratio of 2.31 and price-to-tangible-book ratio of 2.31 indicate that the company's market value is trading at a premium to its book value. The enterprise value to EBITDA ratio of 33.61 suggests a high valuation relative to earnings, which may reflect investor expectations of future growth or industry-specific dynamics. Profitability metrics show a return on equity of 7.18% and a return on assets of 3.29%, both of which are below the typical thresholds for high-performing specialty chemical firms. The gross profit margin of 23.25% (calculated from gross profit of 1.03 billion CNY on revenue of 4.44 billion CNY) is in line with industry norms, but the operating margin of 6.21% (calculated from operating income of 275.31 million CNY) is relatively low, indicating potential cost pressures or pricing challenges. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment and geographic diversification increases exposure to sector-specific and regional economic risks. Looking ahead, the company is expected to see a 22.5% increase in revenue in the current fiscal year, based on analyst estimates of 0.49 CNY EPS compared to the actual 0.40 CNY EPS. However, the capital expenditure of -185.10 million CNY suggests a reduction in investment, which may impact long-term growth potential. The risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund operations or pursue strategic initiatives without external financing. Recent events include a strong buy recommendation from one analyst, with no other analyst ratings provided. The absence of additional analyst coverage may limit the availability of independent insights into the company's performance and prospects.
Key takeaways
  • The company has a moderate debt load and a current ratio of 1.7, indicating acceptable short-term liquidity.
  • Return on equity of 7.18% is below the industry average, suggesting room for improvement in capital efficiency.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • Analysts have issued one strong buy recommendation, but no other ratings are available.
  • The company is expected to see a 22.5% increase in revenue in the current fiscal year.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$4.44B
Gross profit$1.03B
Operating income$275.3M
Net income$220.6M
R&D
SG&A
D&A
SBC
Operating cash flow$305.0M
CapEx-$185.1M
Free cash flow$75.1M
Total assets$6.70B
Total liabilities$3.63B
Total equity$3.07B
Cash & equivalents
Long-term debt$2.17B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$4.44B$275.3M$220.6M$75.1M
FY-1$3.99B$135.7M$101.9M$55.5M
FY-2$3.90B$331.4M$298.7M$24.3M
FY-3$3.71B$318.1M$291.7M-$43.1M
FY-4$2.95B$241.3M$227.4M-$83.0M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$6.70B$3.07B
FY-1$6.59B$2.80B
FY-2$6.20B$2.88B
FY-3$5.99B$2.72B
FY-4$4.38B$2.20B
PeriodOCFCapExFCFSBC
FY0$305.0M-$185.1M$75.1M
FY-1$183.3M-$106.0M$55.5M
FY-2$672.2M-$283.3M$24.3M
FY-3$133.6M-$352.9M-$43.1M
FY-4$122.6M-$361.5M-$83.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$1.16B$97.2M$83.8M
FQ-1$1.15B$8.1M$4.7M
FQ-2$1.12B$91.8M$73.4M
FQ-3$1.10B$80.8M$61.0M
FQ-4$1.07B$95.8M$81.5M
FQ-5$960.2M-$48.0M-$61.3M
FQ-6$1.02B$32.4M$26.3M
FQ-7$1.04B$65.4M$57.4M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$6.85B$3.16B$1.03B
FQ-1$6.70B$3.07B
FQ-2$6.71B$3.02B$630.4M
FQ-3$6.47B$2.88B
FQ-4$6.59B$2.89B$662.3M
FQ-5$6.59B$2.80B
FQ-6$6.55B$2.93B$593.4M
FQ-7$6.47B$2.90B
PeriodOCFCapExFCFSBC
FQ0$9.4M-$39.9M
FQ-1$305.0M-$185.1M
FQ-2$143.2M-$117.5M
FQ-3$29.2M-$63.4M
FQ-4$62.2M-$28.0M
FQ-5$183.3M-$106.0M
FQ-6$116.0M-$75.8M
FQ-7-$40.3M-$53.2M
Valuation
Market price$12.67
Market cap$7.09B
Enterprise value$9.25B
P/E32.1
Reported non-GAAP P/E
EV/Revenue2.1
EV/Op income33.6
EV/OCF30.4
P/B2.3
P/Tangible book2.3
Tangible book$3.07B
Net cash-$2.17B
Current ratio1.7
Debt/Equity0.7
ROA3.3%
ROE7.2%
Cash conversion1.4%
CapEx/Revenue-4.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric300041Activity
Op margin6.2%0.4% medp25 -8.0% · p75 16.0%above median
Net margin5.0%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin23.3%20.8% medp25 14.9% · p75 24.0%above median
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-4.2%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity71.0%59.0% medp25 54.9% · p75 72.9%above median
Observations
IR observations
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.49 CNY
Last actual EPS0.40 CNY
Mean revenue estimate5,120,000,000 CNY
Last actual revenue4,435,572,000 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 01:08 UTCJob: 7bf5b95c